{"symbol":"ABT","fiscalQuarter":"Q2-2026","reportDate":"2026-07-16","reportTime":"BMO","status":"upcoming","company":{"name":"Abbott Laboratories","sector":"Health Care","industry":"Health Care Equipment"},"tier":"free","webUrl":"https://earningsnxt.ai/ticker/ABT/earnings/Q2-2026","estimates":{"consensusEps":1.2772,"consensusRevenue":12536.09,"epsLow":1.26,"epsHigh":1.29,"whisperEps":null,"numAnalysts":null},"preBrief":{"companySnapshot":"Abbott Laboratories (ABT) is a global health care company that develops and manufactures a wide range of medical devices, diagnostics, and nutritional products. With a market cap of $158 billion, Abbott plays a crucial role in the health care sector, particularly in areas like diabetes care and cardiovascular health.","keyMetrics":[{"name":"EPS","why":"Earnings per share is a key indicator of profitability and is closely watched by investors.","consensus":"$1.28"},{"name":"Revenue","why":"Total revenue shows the company's ability to generate sales and is critical for assessing growth.","consensus":"$12.5B"}],"lastQuarterRecap":{"summary":"In Q1-2026, Abbott reported an EPS of $1.15, slightly beating expectations. However, the stock dropped 6% the following day, indicating investor caution despite the earnings beat.","promises":[]},"wallStreetExpectations":{"summary":"Analysts expect Abbott to report solid earnings this quarter, with a consensus EPS of $1.28. However, the stock's recent performance suggests that investors may be cautious about potential future growth.","bullCase":"If Abbott exceeds EPS expectations and shows strong revenue growth, it could signal robust demand for its products, boosting investor confidence.","bearCase":"Conversely, if Abbott fails to meet expectations or provides weak guidance, it could lead to further stock declines, especially given the recent negative reactions to earnings reports."},"optionsSignal":{"impliedMove":"8.67%","context":"The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings announcement."},"earningsTrackRecord":[{"quarter":"Q1-2026","epsSurprise":"+0.61%","reaction":"-6.00%"},{"quarter":"Q4-2025","epsSurprise":"+0.20%","reaction":"-10.04%"},{"quarter":"Q3-2025","epsSurprise":"+0.15%","reaction":"-2.87%"},{"quarter":"Q2-2025","epsSurprise":"+0.80%","reaction":"-8.52%"},{"quarter":"Q1-2025","epsSurprise":"+1.96%","reaction":"+2.76%"}],"pivotalQuestions":[{"question":"Will Abbott's EPS exceed the consensus estimate of $1.28?","whyItMatters":"A strong EPS could reassure investors about the company's profitability and growth potential."},{"question":"What guidance will Abbott provide for future revenue growth?","whyItMatters":"Future revenue guidance will be critical for assessing the company's outlook and could significantly impact stock performance."}],"thesisBreakLevels":{"bullTrigger":"An EPS of $1.30 or higher would confirm the bull case, indicating strong profitability.","bearTrigger":"An EPS below $1.26 would confirm the bear case, suggesting weakening performance.","context":"The market is debating Abbott's ability to sustain growth in a competitive health care environment."},"scenarioPlaybook":{"beatAndRaise":"If Abbott beats expectations, history suggests the stock could rise by around 4.62%, confirming positive investor sentiment.","inLineCautious":"If results are in line with expectations but management is cautious, the stock may remain flat or see a slight decline.","miss":"If Abbott misses expectations, history indicates a potential drop of around 3.34%, reflecting investor disappointment."},"whatTheStreetIsMissing":{"thesis":"The Street may underestimate Abbott's growth potential in emerging markets, which could drive higher-than-expected revenue.","supportingPoints":["Recent product launches in diabetes care have shown strong initial demand, which may not be fully reflected in consensus estimates.","The options market is pricing in a larger move than historical averages, indicating potential for a significant surprise."],"riskToConsensus":"If Abbott's revenue growth exceeds $12.7B, it could challenge the current cautious outlook."},"whatToListenFor":["Any updates on new product launches in the diabetes care segment.","Management's commentary on market conditions and competitive pressures.","Details on revenue growth in international markets.","Insights into supply chain stability and its impact on production.","Any changes in guidance for the upcoming quarters."],"metaDescription":"Abbott Laboratories (ABT) reports Q2 2026 earnings on July 16. Analysts expect $1.28 EPS on $12.5B revenue. Here's what to watch."}}